|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF581 |
Gene summary for ZNF581 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF581 | Gene ID | 51545 |
| Gene name | zinc finger protein 581 | |
| Gene Alias | HSPC189 | |
| Cytomap | 19q13.42 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9P0T4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51545 | ZNF581 | HCC2_Meng | Human | Liver | HCC | 2.83e-07 | 2.33e-02 | 0.0107 |
| 51545 | ZNF581 | cirrhotic1 | Human | Liver | Cirrhotic | 7.99e-05 | 8.62e-02 | 0.0202 |
| 51545 | ZNF581 | cirrhotic2 | Human | Liver | Cirrhotic | 2.85e-02 | 1.21e-01 | 0.0201 |
| 51545 | ZNF581 | cirrhotic3 | Human | Liver | Cirrhotic | 6.30e-03 | 8.61e-02 | 0.0215 |
| 51545 | ZNF581 | Pt13.b | Human | Liver | HCC | 2.01e-07 | 8.40e-02 | 0.0251 |
| 51545 | ZNF581 | S014 | Human | Liver | HCC | 5.42e-31 | 9.74e-01 | 0.2254 |
| 51545 | ZNF581 | S015 | Human | Liver | HCC | 1.14e-23 | 1.17e+00 | 0.2375 |
| 51545 | ZNF581 | S016 | Human | Liver | HCC | 7.24e-19 | 7.71e-01 | 0.2243 |
| 51545 | ZNF581 | S027 | Human | Liver | HCC | 7.34e-03 | 5.15e-01 | 0.2446 |
| 51545 | ZNF581 | S028 | Human | Liver | HCC | 3.77e-16 | 7.19e-01 | 0.2503 |
| 51545 | ZNF581 | S029 | Human | Liver | HCC | 4.76e-13 | 7.61e-01 | 0.2581 |
| 51545 | ZNF581 | C04 | Human | Oral cavity | OSCC | 6.27e-12 | 7.28e-01 | 0.2633 |
| 51545 | ZNF581 | C21 | Human | Oral cavity | OSCC | 2.71e-23 | 7.16e-01 | 0.2678 |
| 51545 | ZNF581 | C30 | Human | Oral cavity | OSCC | 6.43e-36 | 1.25e+00 | 0.3055 |
| 51545 | ZNF581 | C38 | Human | Oral cavity | OSCC | 5.11e-06 | 6.91e-01 | 0.172 |
| 51545 | ZNF581 | C43 | Human | Oral cavity | OSCC | 3.17e-76 | 1.20e+00 | 0.1704 |
| 51545 | ZNF581 | C46 | Human | Oral cavity | OSCC | 1.24e-21 | 5.19e-01 | 0.1673 |
| 51545 | ZNF581 | C51 | Human | Oral cavity | OSCC | 4.82e-08 | 4.50e-01 | 0.2674 |
| 51545 | ZNF581 | C57 | Human | Oral cavity | OSCC | 3.56e-07 | 3.64e-01 | 0.1679 |
| 51545 | ZNF581 | C06 | Human | Oral cavity | OSCC | 1.72e-04 | 6.84e-01 | 0.2699 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF581 | MAST | Cervix | ADJ | TPSAB1,TCEAL3,SIGLEC6, etc. | 4.32e-01 |  |
| ZNF581 | MAST | Cervix | CC | TPSAB1,TCEAL3,SIGLEC6, etc. | 8.90e-02 |  |
| ZNF581 | BN | Cervix | Healthy | TPSAB1,TCEAL3,SIGLEC6, etc. | 8.13e-02 |  |
| ZNF581 | MAST | Cervix | HSIL_HPV | TPSAB1,TCEAL3,SIGLEC6, etc. | 2.57e-01 |  |
| ZNF581 | BN | Cervix | N_HPV | TPSAB1,TCEAL3,SIGLEC6, etc. | 1.23e-01 |  |
| ZNF581 | M2MAC | Esophagus | ADJ | BOD1,DVL1,MRPL48, etc. | 2.37e-01 |  |
| ZNF581 | M2MAC | Esophagus | ESCC | BOD1,DVL1,MRPL48, etc. | 2.39e-01 |  |
| ZNF581 | SEC | Liver | Cirrhotic | METTL18,GEMIN4,FCN2, etc. | 1.11e-01 |  |
| ZNF581 | SEC | Liver | HCC | METTL18,GEMIN4,FCN2, etc. | 1.43e-01 |  |
| ZNF581 | PVA | Liver | HCC | METTL18,GEMIN4,FCN2, etc. | 1.88e-02 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF581 | insertion | In_Frame_Ins | novel | c.221_222insGCCAGGGGCCAGTGTGGCTCCAGGCCAGAAAAAGTGCAACAGCTG | p.Ser78_Gly79insValAlaProGlyGlnLysLysCysAsnSerTrpProGlyAlaSer | p.S78_G79insVAPGQKKCNSWPGAS | Q9P0T4 | protein_coding | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| ZNF581 | SNV | Missense_Mutation | novel | c.47C>T | p.Ser16Phe | p.S16F | Q9P0T4 | protein_coding | tolerated(0.08) | possibly_damaging(0.837) | TCGA-C5-A2LV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF581 | SNV | Missense_Mutation | c.329N>G | p.Ser110Trp | p.S110W | Q9P0T4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A439-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| ZNF581 | SNV | Missense_Mutation | novel | c.142N>T | p.Pro48Ser | p.P48S | Q9P0T4 | protein_coding | tolerated(0.53) | benign(0) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| ZNF581 | SNV | Missense_Mutation | c.289G>A | p.Glu97Lys | p.E97K | Q9P0T4 | protein_coding | tolerated(0.35) | benign(0.148) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF581 | SNV | Missense_Mutation | novel | c.63G>T | p.Glu21Asp | p.E21D | Q9P0T4 | protein_coding | tolerated(0.2) | benign(0.005) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| ZNF581 | deletion | Frame_Shift_Del | c.17delN | p.Cys8AlafsTer105 | p.C8Afs*105 | Q9P0T4 | protein_coding | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |||
| ZNF581 | SNV | Missense_Mutation | novel | c.63G>T | p.Glu21Asp | p.E21D | Q9P0T4 | protein_coding | tolerated(0.2) | benign(0.005) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ZNF581 | SNV | Missense_Mutation | novel | c.238G>A | p.Ala80Thr | p.A80T | Q9P0T4 | protein_coding | tolerated(0.53) | benign(0.006) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF581 | SNV | Missense_Mutation | novel | c.339N>T | p.Lys113Asn | p.K113N | Q9P0T4 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |